CTSS and breast carcinoma: The cathepsin-dependent downregulation of LAMPs increases drug sensitivity in human colon and breast carcinoma cells, while the increase in LAMP levels by cathepsin inhibitors protects transformed cells against the lysosomal cell death pathway.